Navigation Links
Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
Date:7/23/2008

- Company Will Request Hearing to Present Plans for Regaining Compliance -

- NASDAQ Hearing Panel Has Discretion to Grant Peregrine Up to an

Additional 180 Days to Regain Compliance - - Peregrine Currently Meets All Other NASDAQ Capital Market Initial Listing

Requirements Other Than the $1.00 Minimum Bid Price Rule -

TUSTIN, Calif., July 23 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), today announced that it received a Staff Determination letter from the Nasdaq Stock Market (NASDAQ) on July 22, 2008 indicating that the company is not in compliance with the $1.00 minimum bid price requirement for continued listing set forth in NASDAQ Marketplace Rule 4310(c)(4). As a result, the company's common stock would be subject to delisting from the NASDAQ Capital Market unless Peregrine requests a hearing before the NASDAQ Listing Qualifications Panel (the "Panel"). Peregrine intends to request a hearing before the Panel, which will stay the delisting of the company's securities pending the Panel's decision. Rule 4805(a) provides that all hearings shall be scheduled, to the extent practicable, within 45 days of the date that the request for hearing is filed.

At the hearing, Peregrine intends to request continued listing on the NASDAQ Capital Market based upon its plan for regaining compliance with the minimum bid price requirement. Pursuant to NASDAQ Marketplace Rule 4802(b), the Panel has the authority to grant Peregrine up to an additional 180 days from the date of the Staff Determination letter of July 22, 2008 (i.e. January 19, 2009) to implement its plan of compliance, which could include a reverse stock split if the price has not exceeded $1.00 per share for 10 conse
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... August 21, 2014 ... has announced the addition of the  "Global ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... therapy, is a means of replacing hormones ... the body. This type of therapy is ...
(Date:8/21/2014)... -- Mathematic studies at the Program for Evolutionary Dynamics ... the Jeffrey Epstein VI Foundation , have shown that ... for elimination. These aggressive cells are the driver mutations that ... map of what to look for when examining tumors, comes ... cells can be extracted from biopsy, it,s very difficult to ...
(Date:8/21/2014)... Sofia, Bulgaria (PRWEB) August 21, 2014 ... was released today by Ontotext . Now ... and semantic analysis of structured and unstructured data is ... of the cost of enterprise technology. Organizations that do ... approaches for data management can use S4 since there ...
(Date:8/20/2014)... analysis of patented university inventions licensed to biotechnology ... to commercialization. To open these roadblocks, the researchers ... during the discovery stage could lead to faster ... frequently derived from discoveries made in university laboratories ... known during clinical trials, which have a high ...
Breaking Biology Technology:Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3
... of assay of cell-mediated ... immunity, ... data on the monitoring of cell-mediated immunity (CMI) in adult patients,undergoing heart ... demonstrated that ImmuKnow(R) values,appear to closely reflect the immune function of the ...
... REHOVOT, Israel and JERSEY CITY, New Jersey, April ... leader in,the development of microRNA-based diagnostics and therapeutics, ... upcoming annual AACR,conference in San Diego. The posters ... and how they may be applied to develop,objective ...
... Zentaris Inc.,(Nasdaq: AEZS TSX: AEZ;), a global biopharmaceutical ... that David J. Mazzo, Ph.D.,has resigned as President ... the,Board of Directors of AEterna Zentaris, effective immediately. ... of AEterna Zentaris, has been,appointed as the interim ...
Cached Biology Technology:Immune Function in Adult Heart Transplant Patients Reflects Risk for Organ Rejection and Infection 2Immune Function in Adult Heart Transplant Patients Reflects Risk for Organ Rejection and Infection 3Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 2Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 3Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 4Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 5AEterna Zentaris Announces Changes to its Management Team 2
(Date:8/22/2014)... reductase (DHCR24) is a multifunctional enzyme ... and has neuroprotective and cholesterol-synthesizing activities. ... caused by amyloid β deposition. Dr. ... University in China constructed two recombinant ... DHCR24 expression specifically in neuronal cells. ...
(Date:8/21/2014)... in past decade, GTA still violates Canada,s ozone ... the Greater Toronto Area (GTA) has significantly reduced ... the city continues to violate the Canada-wide standards ... or aggravate health problems such as asthma, emphysema ... of complex photochemical reactions involving volatile organic compounds ...
(Date:8/21/2014)... to ignore, but they are the ultimate source of ... are increasingly dependent on algae, too, to suck up ... to the bottom of the ocean. Now, by using ... have evidence showing that viruses infecting those algae are ... when all else stays essentially the same, and this ...
Breaking Biology News(10 mins):Despite a significant reduction in smog-producing toxins, the Greater Toronto Area still violates Canada's standards for ozone air pollution 2Viruses take down massive algal blooms, with big implications for climate 2
... Human activities are degrading the Amazonian forest at twice ... adds the effects of logging to those of clear-cutting. ... the journal Science , published by AAAS, the ... measuring deforestation across large areas have only been capable ...
... effective vaccines for people with compromised immune systems ... team of researchers, who demonstrated their approach could ... same population of immune cells that HIV destroys ... Hospital of Pittsburgh researchers, working in collaboration with ...
... model systems for understanding fungal diseases, two groups of ... how carbon dioxide (CO2) governs the morphogenic changes that ... invade the human body, and they provide new evidence ... enzymes to control the growth and sexual reproduction of ...
Cached Biology News:Logging doubles threat to the Amazon, rivaling clear-cutting, study suggests 2New vaccine platform may fight infections with causes from influenza to bioterrorism 2New vaccine platform may fight infections with causes from influenza to bioterrorism 3CO2 sensing proves critical for fungal pathogens to adapt to life in air and human hosts 2CO2 sensing proves critical for fungal pathogens to adapt to life in air and human hosts 3